Effects of Adding Ivabradine in Patients With Cardiogenic Shock Requiring Inotropic Support
Status: Unknown
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
Data regarding the safety and efficacy of ivabradine use in severely decompensated HFrEF requiring inotropic support is limited to case series.1 This study aimed to evaluate ivabradine safety and tolerability in admitted cardiogenic shock patients who started on dobutamine infusion for inotropic support.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Decompensated heart failure with reduced ejection fraction (HFrEF) admitted for cardiogenic shock requiring inotropic support.
Locations
Other Locations
Egypt
Andalusia Hospitals
NOT_YET_RECRUITING
Alexandria
Tiba Hospital
RECRUITING
Alexandria
Contact Information
Primary
Abdallah Almaghraby, PhD
dr.maghraby@gmail.com
+201222851687
Backup
Mahmoud Abdelnabi, MD
mahmoud.hassan.abdelnabi@gmail.com
+18065897577
Time Frame
Start Date: 2022-07-01
Completion Date: 2023-01-01
Participants
Target number of participants: 200
Treatments
Experimental: Ivabradine+ dobutamine infusion
Patients will receive ivabradine 7.5 mg twice daily via oral route after starting dobutamine infusion by 30 minutes.
Active_comparator: Dobutamine infusion only
Patient will receive dobutamine infusion only for cardiogenic shock
Related Therapeutic Areas
Sponsors
Leads: The Young Investigator Group of Cardiovascular Research